INTRODUCTION

Type 2 diabetes (T2DM) is a major health and economic concern for the Western World. In the UK in 2018, 26% of the population over 65 are diagnosed, and 56% of these are men. The prevalence is 6 times greater in men of South East Asian origin and 3 times greater in men of Afro-Caribbean background [1]. In the US, two-thirds of men over 65 have T2DM. The United Kingdom Prospective Diabetes Study (UKPDS) confirmed that each increase of 1% increases risk of diabetes related death by 21%, myocardial infarction (MI) by 14%, and peripheral vascular disease by 43% [2]. Currently all men diagnosed with T2DM over age...
40 are routinely commenced on metformin, statin and angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), as preventive strategies according to the National Institute for Health and Care Excellence (NICE) guidance [3]. In an age of “personalised” care in diabetes, we analyse the journey of a well-informed, newly diagnosed patient with T2DM to evaluate the current evidence for routine use of phosphodiesterase type 5 (PDE5) inhibitors.

A PATIENT EXPERIENCE

This is an imaginary case based on the author’s experience. The names of the characters are fictitious.

Roger is an experienced solicitor, 50, has been recently diagnosed with T2DM at a routine medical with hemoglobin A1C 6.6 mmol/mol (International Federation of Clinical Chemistry and Laboratory Medicine, 48%). He is slightly overweight (body mass index, 28.5 kg/m²), blood pressure 125/80 mmHg, total cholesterol 5.1 mg/dL, and high-density lipoprotein 1.6 mg/dL. He is otherwise fit, exercises regularly and is happily married to Janet for 20 years. His father was diagnosed with T2DM in his 50s, suffered from leg ulcers and died of a heart attack at 64. Roger’s sex life is OK but not what it used to be, and he passes urine a lot more frequently, especially at night and with a weak stream. He explains that his father also had an enlarged prostate, kidney failure and required two transurethral resections of the prostate. His general practitioner (GP) commencement him on ramipril 5 mg, atorvastatin 20 mg and metformin 500 mg twice daily, explaining that this is routine for all patients. He is not asked about his erections, despite the NICE guidance, so he asks the diabetes nurse what the diagnosis of T2DM means for his sex life. She seems very surprised to be asked and offers reassurance plus a leaflet for newly diagnosed patients that mentions nothing about erectile dysfunction (ED).

ERECTILE DYSFUNCTION

Roger does some research and is shocked to read that he has a 70% chance of developing ED [4] with a 55% (at best) response to oral therapy once the problem is diagnosed [5]. He wonders why he is taking 3 medications to prevent complications with a much lower incidence. He reads that ED in diabetes is due to multiple mechanisms (Table 1) primarily “endothelial dysfunction”, which is a chronic disorder potentially affecting all his blood vessels, with ED presenting first as it is

Table 1. Erectile dysfunction in type 2 diabetes mellitus (related to duration, control and number of complications)

| Condition                                                                 |
|---------------------------------------------------------------------------|
| Autonomic neuropathy                                                      |
| Peripheral neuropathy                                                     |
| Hypertension                                                              |
| Peripheral vascular disease                                               |
| Dyslipidemia                                                              |
| Drug side effects                                                         |
| Benign prostatic hyperplasia (lower urinary tract symptoms)              |
| Depression                                                                |
| Hypogonadism (double risk)                                               |
| Psychological Factors                                                    |
| Plus ejaculatory disorders. Retrograde/Anejaculation                      |
| Reduced sensation                                                         |

Fig. 1. Mechanism of endothelial dysfunction in type 2 diabetes. NO: nitric oxide, PDE5: phosphodiesterase type 5.
affecting smaller arteries [6] (Fig. 1). He reads that ED with diabetes increases his risk of heart disease within 3–5 years by 50% [7]. Further research suggests that an ARB might have been better for his erections than an ACE inhibitor, and he wonders why this was not discussed [8].

He reads that, as a newly diagnosed man with T2DM, he has a 30% chance of diabetic peripheral neuropathy (DPN) [2], and 32% increased risk of lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH [9]).

Roger returns to see his GP as he is having problems sustaining an erection and is prescribed 4 tablets of sildenafil 25 mg. Roger asks whether his testosterone might be measured as he has seen on the internet that men with T2DM may have a low testosterone but his GP points to Roger’s fine beard and concludes that he is unlikely to have such a problem.

Roger and Janet have been used to a very active sex life, but they restrict activity to once per week after receiving the prescription, but they find the planning awkward and the medication ineffective. Roger is also noticing that his stream is getting worse and he is getting up to pass urine 3 times per night. His GP increases his sildenafil to 50 mg and gives him 4 further tablets. He performs a digital rectal examination and checks his prostate-specific antigen and commences tamsulosin 400 μg daily having confirmed a “slightly enlarged” prostate. Roger discontinues both medications after 2 weeks as he is losing his erection and finds it impossible to ejaculate. He is feeling depressed about the whole situation.

CURRENT NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE, AMERICAN DIABETES ASSOCIATION, AND EUROPEAN UROLOGICAL ASSOCIATION GUIDANCE

Essentially the care that Roger has received is in line with current UK practice for BPH [10]. Although the NICE Guidance in T2DM [3] suggests annual assessment of ED, reviews by Schartau et al [11] and David et al [12] shows that this happens in less than 25% of men. In fact, Schartau et al [11] showed that, only for 1 year in 2013 did this improve, when GPs were specifically paid in their contact. When this payment was withdrawn in 2014, the impact was lost. This effect was mirrored in a transient increase in prescribing of ED drugs and testosterone measurement. These findings suggested that financial payment was a major driver for changes in practice [11]. NICE advice is that men with T2DM and ED should be offered “a PDE5 inhibitor with the lowest acquisition cost”, which is sildenafil 25 mg and “4 tablets per month maximum” [3]. Multiple randomized controlled trials (RCTs) have shown that, at best 50% of patients succeed with “on-demand” PDE5 inhibitors even at the highest dose and with unrestricted medication [13]. The mechanism of ED in T2DM is predominantly endothelial dysfunction, a chronic pathology affecting the entire cardiovascular system, such that a single tablet of sildenafil with a half-life of 4 hours is unlikely to affect the underlying progressive pathological process. The multiple pathologies involved in ED in T2DM are outlined in Table 1. Effectively Roger was unlikely to achieve success [13].

Men with T2DM have a 32% higher prevalence of LUTS/BPH due to shared mechanisms of chronic inflammation, insulin resistance, endothelial dysfunction, pelvic atherosclerosis and sympathetic overactivity [9] but first line NICE advice for men with minimal prostate enlargement is an alpha-blocker [10], known to adversely affect ejaculation, which may already be affected by neuropathy in men with T2DM [9]. In addition, the co-prescribing with an on-demand PDE5 inhibitor is more likely to produce symptomatic hypotensive episodes in men with T2DM [14,15], due to co-morbid autonomic neuropathy, co-prescribed anti-hypertensives and hypoglycaemia.

European Urological Association and British Society for Sexual Medicine (BSSM) guidelines [16,17] do recommend daily tadalafil as first line for men with ED and LUTS but unfortunately this strategy is not even considered by NICE, nor are Diabetes specialists likely to motivated to follow urology or sexual medicine guidelines.

Likewise, American Urological Association [18], American Diabetes Association [19], American Association of Clinical Endocrinologists [20] and BSSM guidelines [21] do recommend Testosterone measurement in men with T2DM, with or without ED, but Testosterone is not considered in current NICE guidance on T2DM and there is no NICE guidance on ED, even after 21 years of PDE5 inhibitors.
THE CASE FOR DAILY TADALAFIL 5 mg FOR ENDOTHELIAL DYSFUNCTION IN MEN WITH TYPE 2 DIABETES

ED is now acknowledged as an independent risk factor for cardiovascular events and mortality [17,22], increasing the risk by 50% in men with T2DM. ED has now been introduced into cardiovascular risk calculators [23]. Modern cardiovascular risk strategies revolve around reducing the impact of the modifiable risk factors as demonstrated in the INTERHEART study [24]. It is therefore logical that ED should be approached in the same fashion as other independent risk factors. The chronic pathological process is endothelial dysfunction, and this has been shown to be modified by chronic PDE5 inhibitors in many studies [3]. Rosano et al [25] demonstrated significant improvement in endothelial function after 2 weeks, that persisted 2 weeks after treatment cessation. Amano et al [26] investigated 81 men with ED and LUTS treated with tadalafil for 12 months and found significant improvements in international index of erectile function (IIEF) at 3 months (continuing improvement at 12 months), international prostate symptom score (IPSS) after 1 month, brachial-ankle pulse wave velocity and ankle-brachial index after 3 months. Ramirez et al [27] investigated 21 men with pre-diabetes treated with sildenafil 50 mg daily for 3 months and found significant improvements in insulin sensitivity, PA-1 and albumen-creatinine ratio. Santi et al [28] investigated 54 men with T2DM in a 24-week placebo-controlled study of vardenafil 10 mg BD and found significant improvements in IIEF, Flow mediated dilatation, interleukin (IL)-6, and testosterone levels in the cohort with hypogonadism. Aversa et al [29] investigated 45 men with diabetes treated with either 5 mg tadalafil daily or 20 mg on-demand and found that only daily tadalafil improved flow mediated dilatation, insulin sensitivity and lean muscle mass. Fiore et al [30] demonstrated positive changes in adipocytes and browning of fat in obese men undergoing biopsy of visceral fat after only 7 days 100 mg of sildenafil vs. placebo.

Santi et al [31] conducted a meta-analysis of 12 RCTs (n=476) of chronic PDE5 inhibitors in T2DM and concluded clear evidence of improved flow mediated dilatation and reduction of IL-6, with high-sensitivity C-reactive protein (hs-CRP) improvement just failing to reach statistical significance. Selected studies involved sildenafil (25–100 mg daily), usually for 12-week maximum duration.

Lee at al [32] conducted a 12-week study of tadalafil 5 mg daily in men with T2DM and found that severity of ED was related to baseline hs-CRP. Response rate, based on Sexual Encounter Profile (SEP) 3 was 70% Median hs-CRP levels were 0.31 mg/dL (range, 0.18–0.62 mg/dL) in non-responders and 0.14 mg/dL (range, 0.09–0.4 mg/dL) in responders, respectively (p=0.028).

Schwartz et al [33] reviewed studies of tadalafil 5 mg daily on endothelial function and suggested that these effects might translate into a long-term reduction in cardiovascular risk.

DAILY TADALAFIL EFFECTS ON TESTOSTERONE LEVELS

Men with T2DM have low levels of testosterone in up to 40% with associated cardiovascular risk [1]. Many may be candidates for testosterone therapy to improve sexual symptoms, quality of life and cardiovascular risk. Hellstrom et al [34], in a placebo-controlled study designed to assess sperm parameters in 253 men treated with tadalafil 20 mg for 3 months found significant increases in total testosterone vs. placebo and no significant effect on semen parameters over 3 cycles. Ozcan et al [35] treated 40 men with metabolic syndrome with tadalafil 5 mg for 3 months with an increase of testosterone from 11.4 (baseline) to 16.5 nmol/L, and IIEF-5 from 11.3 to 19. The authors recommend tadalafil 5 mg once daily in those men with ED especially low testosterone levels accompanied by metabolic syndrome. Spitzer et al [36] treated 106 men with sildenafil 50–100 mg for 3–7 weeks (mean 2.6 doses on demand per week) and found a mean rise of 3.6 nmol/L and corresponding fall in luteinizing hormone. The authors suggested that the beneficial effect on androgen levels might be related to a direct effect of testicular blood flow rather than increased sexual activity. These studies suggest a possible beneficial effect on androgen levels if there is a wish for testosterone therapy to be avoided or as an adjunct to testosterone treatment.
THE CASE FOR TADALAFIL 5 mg DAILY FOR ERECTILE DYSFUNCTION IN MEN WITH TYPE 2 DIABETES

Unfortunately, PDE5 inhibitors do not have a licence to treat the process of endothelial dysfunction and are only licensed to treat ED and pulmonary hypertension (sildenafil and tadalafil) [33]. Tadalafil 5 mg daily is licensed to treat LUTS/BPH and is the only PDE5 inhibitor licensed for daily use [14,16]. Physicians employed under health care systems are advised to prescribe only for licensed indications. However, patients should be informed if the choice of one licensed formulation over another confers other health benefits even if that therapy may require funding by the patient. The important question is therefore “does daily tadalafil in T2DM produce better results in terms of sexual function compared with other therapies”? Many “preference studies” were set up to address this question, with conflicting findings largely due to selection bias, inappropriate patient reported outcomes and different dosing advice for different preparations. In the most recent meta-analysis of 16 head to head trials of sildenafil and tadalafil, Gong et al [13] concluded “Tadalafil shares a similar efficacy and safety with sildenafil but tadalafil significantly improves patients’ sexual confidence and quality of life according to multiple outcome measures. Furthermore, patients and their partners prefer tadalafil to sildenafil. Hence, tadalafil may be a better choice for ED treatment” [13]. Park et al [37] assigned 118 men with T2DM and ED to either tadalafil 20 mg on demand or tadalafil 5 mg daily and followed them up for 2 years. The IIEF score improved progressively with daily 5 mg, but not on demand tadalafil 20 mg, 7.2 vs. 2.4 (p<0.0001).

The BSSM guidelines 2018, report that on-demand PDE5 inhibitors are only successful in 50% of men with T2DM [17] despite unlimited medication in clinical trials. Buvat et al [38] reported that 89% of patients switched to daily tadalafil were still taking medication after 12 months. The BSSM guidelines suggest that up to 50% of patients who fail with on-demand therapy respond to daily dosing [17].

Five meta-analyses have compared on-demand vs. daily tadalafil and the findings are reported in Table 2. Brock et al [39] compared only RCTs and concluded equal efficacy but these trials were usually of 12-week duration where on-demand patients were provided with unlimited medication such that total dose of tadalafil was usually significantly higher than 5 mg daily dosing. Bansal et al [40] reviewed 6 head to head studies of up to 12 weeks and concluded that daily tadalafil resulted in a 1.82 higher ED score than 20 mg on-demand. Peng et al [41] included studies of up to 26 weeks and found superiority for tadalafil 5 mg daily especially in men with diabetes and post radical prostatectomy and especially when assessed by SEP, a diary completed daily as opposed to IIEF data which relies on memory of sexual attempts up to 6 months previously. Prasetyo [42] also concluded greater efficacy for once daily (OaD)

| Study                  | Head to head RCTs reviewed                                                                 | Conclusions                                                                 |
|-----------------------|-------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Brock et al (2016)    | 17 prn vs. placebo, 4 OAD vs. placebo (n=4,345) Usually 14 weeks duration                | Efficacy for both treatments across a wide range of pathologies – no significant difference between regimes. |
| Bansal et al (2018)   | 6 RCTs, 2 open label (n=672) 12 weeks duration                                            | Efficacy across a wide range. Erectile function score 1.82 greater for OAD. SEP2 and 3 not assessed. |
| Peng et al (2017)     | 6 RCTS OAD vs. on vs. demand (n=1,534) 8 weeks to 9 months duration                      | Efficacy for both treatments across wide range of pathologies. Superiority for OAD in terms of SEP2 and SEP3, especially in prostate cancer. Patient preference for OAD. |
| Prasetyo et al (2019) | 4 RCTS (n=1,200) Under 14 weeks duration                                                   | Both treatments efficacious but SEP2 and SEP3 superior for OAD tadalafil. |
| Zhou et al (2019)     | 4 RCTs (n=1,035) Greater than 24 weeks SEP2 and 3 was main outcome.                      | SEP2 MD 10.08 (p<0.00001) and SEP3 MD 8.09 (p<0.009). Tadalafil provided greater efficacy and lower side effect profile in RCTs >24 weeks. |

OAD: once daily, RCTs: randomized controlled trials, prn: pro re nata (when needed), SEP2: Sexual Encounter Profile Question 2 (Were you able to achieve an erection suitable for penetration?), SEP3: Sexual Encounter Profile Question 3 (Were you able an erection suitable for the completion of sexual activity?), MD: mean difference.
vs. on-demand tadalafil based on SEP2 and SEP 3 data. Most recently Zhou et al [43] conducted a meta-analysis of 4 studies longer than 26 weeks and concluded that daily tadalafil was associated with greater therapeutic benefit and lower side effect profile and that efficacy increased with duration of therapy. This is an important finding, bearing in mind the progressive deterioration in endothelial function and autonomic neuropathy associated with diabetes and suggests that therapy needs to address the pathological damage and not purely a symptom. Shafik et al [44] demonstrated that loss of morning erections was associated with atrophy of the tunica albuginea and veno-occlusive dysfunction and chronic dosing with PDE5 inhibitors is more likely to prevent this progressive decline.

The impact of tadalafil daily dosing on women partners’ satisfaction with sexual activity has also been a topic of recent interest and research. A partner preference study of on-demand sildenafil vs. tadalafil indicated that 79% of women partners preferred tadalafil, citing a more relaxed approach to sexual intimacy and greater flexibility with respect to timing of intercourse [45]. Based on this, it may be inferred that the flexibility of completely separating medication from sexual activity (as is the case for daily dose therapy) would be appealing to many women partners of men with ED. Women who dislike the idea of partners taking ED therapy might readily accept that their partner takes therapy for “bothersome” BPH and that erections improve as part of that regime.

THE CASE FOR EARLY INTERVENTION OR PREVENTION OF ERECTILE DYSFUNCTION

Several studies suggest that the prevalence of ED in T2DM as assessed by IIEF-5 score of 21 or less is 75% to 77% and is related to duration of diabetes, number of complications and quality of glycaemic control [17]. If current approaches to therapy result in 50% of patients failing to respond to oral therapy, then large numbers are progressing to second- and third-line therapies that, in an age of generic oral drugs results in exponentially higher costs. There are now sound economic reasons for earlier intervention with therapy targeted towards the chronic disease progress, or even prevention. It could be argued that ED progression is virtually inevitable as very few men with T2DM have completely normal IIEF scores and ED often pre-dates the diagnosis of T2DM [46].

As ED is a recognised risk factor that confers an increased cardiovascular risk of 50%, then logically ED to be prevented as would be the case with any other risk factor [22,47]. Regular erections and sexual activity have been shown to protect against ED [48]. It might be reasonable to present these facts to the patient and his partner and allow them to be involved in the discussion as to which stage he would wish daily therapy or even early prevention. Clearly lifestyle advice in relation to ED should always be given at the same time but such interventions should have been implemented as part of standard diabetes care [9,17].

ECONOMIC ISSUES

Generic tadalafil 5 mg costs approximately £5 per month at National Health Service tariff. Every patient in the 45% who subsequently fail with the PDE5I will cost £12–15 for each dose of second line therapy, such as alprostadil or MUSE®, meaning £48–60 per month for sexual activity once per week or £96–120 per month for activity twice per week [49]. Each case will usually require secondary care referral at £120 with an average of three follow-up visits at £80 to teach the injection process. Costs will be greater under health care systems where the patient pay privately. Involving the patient in discussions about the finances of long-term treatment might result in a positive decision towards early therapy or even prevention.

THE CASE FOR TADALAFIL FOR SYMPTOMATIC LOWER URINARY TRACT SYMPTOMS/BENIGN PROSTATIC HYPERPLASIA IN MEN WITH TYPE 2 DIABETES

Over 50% of men over 50 have symptomatic BPH/ LUTS and men with T2DM have a 32% increased risk [4,50]. Among the mechanisms involved in the pathology of BPH/LUTS, the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) pathway has an important functional role, and all key enzymes of this pathway, NO synthase, protein kinase G-1 and PDE5 are expressed in the prostatic tissue. NO exerts a general inhibitory effect of muscle tone on the lower urinary tract. A decrease in NO-mediated relaxation
of smooth prostatic muscle contributes to BPH/LUTS pathology. Latest evidences on the pathophysiology of BPH/LUTS has provided the rationale for use of PDE5-inhibitors: improvement of lower urinary tract (LUT) oxygenation, smooth muscle relaxation, negative regulation of proliferation and trans-differentiation of LUT stroma, reduction of bladder afferent nerve activity, and down-regulation of prostate inflammation are the proven mechanisms of action of PDE5-inhibitors [51].

Head to head trials show equal efficacy for tadalafil compared with tamsulosin, with clinically significant reduction of 5–6 IPSS points but greater patient preference for tadalafil, irrespective of improvements in ED [52,53]. Initial studies failed to show an increase in flow rate but a review by Roehrborn et al [54] in total study population of 1,500 men, patients with tadalafil had significantly greater maximum urinary flow rate (Qmax) improvement (mean, +1.1 mL/s) compared with patients with placebo (mean, +0.4 mL/s; p=0.003), significant Qmax improvement in the total study population was mainly driven by effects in patients who voided 250–450 mL (p=0.011) and had a baseline Qmax 10–15 mL/s (p=0.044). Pogula et al [55] published a 12-week comparative study of tadalafil vs. tamsulosin in BPH and found superiority for tamsulosin in terms of IPSS and Qmax but marked superiority for tadalafil for IIEF. A review by Hatzimouratidis [56] pointed out that head to head comparison in 12-week studies were unhelpful due to the different mechanism of action of the drugs, improvement of co-morbid ED and that long-term studies of disease progression are more relevant. Donatucci et al [57] showed that IPSS scores with tadalafil were still improving after 1 year of open label use and that improvements in erectile function were maintained.

One RCT showed significant improvement with tadalafil 5 mg daily in the bothersome symptom of post-micturition dribble, whereas tamsulosin has proved ineffective [58]. Studies suggest a synergistic effect with tadalafil in combination with tamsulosin, and, for larger prostates with finasteride. A recent UK DATA-LINK study has suggested a possible 30% increased risk of T2DM in men taking 5α-reductase inhibitors, and caution in their use in men with metabolic syndrome [59].

A recent meta-analysis supported the rationale for tadalafil/finasteride in terms of preservation in sexual function in comparison with tamsulosin/finasteride, an effect likely to be more important in men with BPH and T2DM where multiple co-morbidities for ED are likely to be present [60].

THE CASE FOR TADALAFIL FOR BENIGN PROSTATIC HYPERPLASIA PREVENTION IN TYPE 2 DIABETES

Over two-thirds of men over 50 with T2DM suffer from some degree of LUTS as assessed by IPSS [4]. Alpha-blockers, as first line BPH therapy for decades, are more likely to be associated with drug interactions and hypotension in men with T2DM, especially those on multiple anti-hypertensive regimes or those subject to hypoglycaemia. Older, frail men treated with alpha-blockers may be at greater risk of falls, especially related to increased micturition at night [61].

Alpha-blockers have consistently shown to have no effect of BPH progression as sole therapy [62]. BPH progression has considerable health economic consequence that add to the huge economic burden of T2DM [62]. Long-term data on prostate size and disease progression with tadalafil are required to address this question but a review by Gacci et al [63] suggests that improved endothelial dysfunction and reduction of inflammatory markers suggest optimism that daily tadalafil might reduce BPH progression. As 75% of men with T2DM are likely to suffer ED and ejaculatory problems due to vascular and neuropathic complications of T2DM, studies reporting “volunteered” sexual complications are highly likely to underestimate the true impact of both alpha-blockers and finasteride, as reported by Seftel et al [64]. The MSAM-7 study clearly showed the close association of LUTS severity with lower IIEF scores [50].

EVIDENCE THAT PHOSPHODIESTERASE TYPE 5 INHIBITORS MIGHT REDUCE DIABETES RELATED MORBIDITY AND MORTALITY

PDE5 inhibitors were developed as daily therapy to treat cardiovascular disease and improvements in ED were an incidental finding during clinical trials [3]. Sildenafil and tadalafil are licensed to treat pulmonary hypertension through their beneficial effects on
endothelial dysfunction [3]. Several cardiology reviews have highlighted the beneficial cardiovascular effects that would potentially reduce cardiovascular events in high risk populations such as men with T2DM [3,65-67]. Beneficial mechanisms include improved endothelial function, enhanced cGMP and cyclic adenosine monophosphate (cAMP) activity to counterbalance hypertrophic and pro-apoptotic signalling and enhanced post-ischaemic reperfusion. In vitro experiments suggest likely benefits in patients with heart failure [65]. These mechanisms are highlighted in Fig. 2. Currently tadalafil 5 mg is the only PDE5 inhibitor suitably licensed for daily use [17].

Anderson et al [68] who followed a UK primary care population of 5,956 UK men with T2DM over 6.9 years. A 31% reduction in all-cause mortality and 26% reduction in MI were reported in men taking PDE5 inhibitors. Only 22.8% of men with T2DM had been prescribed a PDE5 inhibitors, with patients usually restricted to once per week. These findings were supported by Hackett et al [69] in a prospective RCT of testosterone therapy in T2DM. The 175 men taking PDE5 inhibitors showed a significant and independent reduction in all-cause mortality.

Andersson et al [70] reported data from a Swedish database of 43,415 men after first MI for 5 years and found significant reduction in all-cause and cardiovascular mortality and 30% reduction in new diagnosis in heart failure and related admissions, in men prescribed PDE5 inhibitors. The benefits were greater in men on more frequent dosing of PDE5 inhibitors and were not seen with other ED therapies.

These 3 studies are subject to potential bias. Men prescribed PDE5 inhibitors would have been likely to have been assessed as “fit or sexual activity” and men taking nitrates would have been excluded. Conversely men prescribed a PDE5 inhibitor would have been suffering from ED, which is known to be associated with 50% addition risk of a cardiovascular event. These studies suggest the need for a long-term placebo-controlled study to address the potential cardio-preventive role of daily PDE5 inhibitors in T2DM but such a study might be problematic given the high rates of ED and the logistic of a placebo arm of several year duration for a highly symptomatic condition such as ED.

Scranton et al [71] carried out a complex health care review and concluded that diagnosis and successful treatment of concomitant ED may promote improved adherence and management of comorbid diseases. Concomitant ED management may improve treatment outcome, decrease healthcare costs, and possibly prevent or even improve deterioration in medical conditions comorbid with ED.

PREVENTION OF DIABETIC PERIPHERAL NEUROPATHY

DPN occurs in approximately 30% of men with T2DM and currently the mainstay of prevention is through tight glycaemic control. There are numerous case reports of improvement in neuropathic pain and paraesthesia with PDE5 inhibitors. NO is the major
neurotransmitter of the vasa nervorum, suggesting an important preventive role in microvascular complications. Currently, drugs used to treat established DPN effectively block pain pathways and frequently aggravate ED. There is huge potential for savings by the prevention of complications of DPN [72,73].

**DIABETIC NEPHROPATHY**

The multiple potential benefits of PDE5 inhibitors in renal disease are as follows; decreases in ischemia reperfusion injury, improves endothelial dysfunction, decreases apoptosis and necrosis, increases NO availability and endothelial nitric oxide synthase, increases mitochondrial biogenesis, decreases DNA damage, decreases renal inflammation, decreases renal fibrosis, increases catalase, increases superoxide dismutase, inhibits lipid peroxidation, decreases activation of and proliferation of mesangial cells, preserves podocyte function and suppresses vascular smooth muscle cell proliferation in the glomerular arterioles [74].

**CANCER PREVENTION**

T2DM is associated with increased risk of many cancers, particularly colon. Review articles suggested a role for PDE5 inhibitors in cancer prevention [75]. In a Swedish national database study, Huang et al [76] studied a total of 4,823 patients who were prescribed PDE5 inhibitors during the study period; the incidence rate of colorectal cancer (CRC) was 2.64 per 1,000 person-years for men prescribed PDE5 inhibitors compared with 4.46 per 1,000 person-years for men without a prescription. They found a significant negative association between PDE5 inhibitor use and risk of CRC (adjusted hazard ratio, 0.65; 95% confidence interval, 0.49–0.85); the decreased risk of CRC was associated with an increased cumulative dose of PDE5 inhibitors (p=0.003).

**COGNITIVE IMPROVEMENT**

Choi et al [77] treated 30 men with ED and mild cognitive impairment with tadalafil 5 mg for 8 weeks. Mean baseline IIEF and Montreal Cognitive Assessment (MoCA) scores were 7.52±4.84 and 18.92±1.78. After the eight-week treatment, mean IIEF and MoCA scores were increased to 12.92±7.27 (p<0.05) and 21.8±1.71 (p<0.05), respectively. Patients showed increased relative regional cerebral blood flow in the postcentral gyrus, precuneus, and brainstem after tadalafl administration versus at baseline (p<0.001).

Urios et al [78] studied 9 patients with LUTS/BPH and ED. Patients with BPH/LUTS-ED showed increased CD4+CD28+ autoreactive T-cells (p<0.05), and higher levels of pro-inflammatory ILs (IL-6, p<0.001; IL-17 and IL-18, p<0.05), compared to controls. Patients achieved lower scores than controls in psychometric tests assessing mental processing speed and attention (p<0.05), and showed lower amplitude (p<0.01) and area (p<0.05) of mismatch negativity (MMN) wave than controls. Inflammatory, psychometric and electrophysiological parameters were normalized after tadalafl treatment. The authors concluded that there is a pro-inflammatory environment in blood in patients with BPH/LUTS-ED which would induce cognitive impairment and alter MMN. Phosphodiesterase-5 inhibition with tadalafl exerts anti-inflammatory effects and ameliorates cognitive function and MMN parameters. The authors concluded that tadalafl could be a promising candidate for chronic treatment in other inflammatory pathologies associated with mild cognitive impairment.

**DEPRESSION**

Depression is twice as common in men with T2DM with prevalence of 25% [79] and sexual disfunction is the complication of T2DM most closely linked with depression. Both ED and LUTS are linked with depression [80]. Nurnberg et al [81] showed that depression score improved when men with ED and moderate depression were treated with sildenafil versus placebo. Shim et al [82] conducted a 2 month placebo controlled in 60 men with ED and with no known cognitive impairment. The changes in the Patient Health Questionnaire (PHQ)-9 and PHQ-15 were 2.04±3.14 and 2.17±2.87 with the PDE5 inhibitor, udenafil given daily, and 1.20±1.63 and 0.56±2.48 in the placebo group (both, p<0.001 for udenafil). The authors concluded that daily dosing with a PDE5 inhibitor seems to improve cognitive function, depression and somatization, as well as erectile function, in patients with ED.
CONCLUSIONS – BACK TO THE PATIENT

Roger returns to his GP with a balanced argument based on his comprehensive research. He states that the impact of ED and BPH are far more relevant for him now than statistical risk reduction for cardiovascular outcomes. He feels that it is more relevant to take a daily medication likely to produce symptomatic improvement within days. From what he has read, the major strategy for improving outcome in T2DM is multiple rather than selective risk factor reduction. He witnessed the poor quality of life that his father experienced with BPH, whilst still a relatively young man and would rather take a treatment that addresses the pathological processes of BPH rather than one repeatedly shown to have no impact on the progression of the disease. He has already experienced mild muscular aches possibly related to his statin, nausea and loose stools with metformin and an irritant cough with ramipril, which eased when he was eventually switched to valsartan. He experienced no side effects with on-demand sildenafil, so is confident that tadalafil at 5 mg will have no adverse effects apart from more frequent erections, which would be greatly appreciated. Unfortunately, his GP states that currently he is restricted from prescribing daily tadalafil and must, under NICE guidance, only prescribe the PDE5 inhibitor with lowest acquisition cost. Roger leaves having decided that he will stop the array of vitamins and antioxidants, taken for many years at vast expense, having read that they do little good and possible harm. He decides to use the savings to self-fund low cost generic tadalafil 5 mg daily. As he leaves, he picks up a diabetes UK leaflet, stressing the importance of targeted, individualised care in diabetes and wonders whether this is what he has been receiving.

Prescribing policies for T2DM are largely decided by diabetes specialists, with priorities given to glycaemic control. Co-morbid conditions such as ED and BPH are usually managed by urologists and publications concerning PDE5 inhibitors largely in urology and sexual medicine journals. The recognition of ED as an independent risk factor for coronary heart disease justifies inclusion in routine risk reduction strategies. Evidence that PDE5 inhibitors produce benefits through multiple mechanisms now supports routine prescribing in diabetes care, not least because the patients will potentially experience symptomatic improvements that will increase compliance with other prescribed interventions.

Conflict of Interest

The author has nothing to disclose.

Author Contribution

Conceptualization: GH. Data curation: GH. Formal analysis: GH. Investigation: GH. Methodology: GH. Project administration: GH. Resources: GH. Software: GH. Supervision: GH. Validation: GH. Visualization: GH. Writing – original draft: GH. Writing – review & editing: GH.

REFERENCES

1. American Diabetes Association. Statistics about diabetes [Internet]. Arlington (VA): American Diabetes Association; [cited 2018 Apr 1]. Available from: http://www.diabetes.org/diabetes-basics/statistics/.
2. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
3. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management [Internet]. London: National Institute for Health and Care Excellence; c2015 [cited 2019 Dec 28]. Available from: https://www.nice.org.uk/guidance/ng28.
4. Hackett GI, Cole NS, Deshpande AA, Popple MD, Kennedy D, Wilkinson P. Biochemical hypogonadism in men with type 2 diabetes in primary care practice. Br J Diabetes Vasc Dis 2009;9:226-31.
5. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 2004;47:1914-23.
6. Jackson G, Nehra A, Miner M, Billups KL, Burnett AL, Buvat J, et al. The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician. Int J Clin Pract 2013;67:1163-72.
7. Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, Aznouiridis KA, Stefanidis CI. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes 2013;6:99-109.
8. Doumas M, Boutari C, Viigimaa M. Arterial hypertension and erectile dysfunction: an under-recognized duo. e-J Cardioi Pract 2016;14:1-7.
9. Kirby M, Chapple C, Jackson G, Eardley I, Edwards D, Hackett G, et al. Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis. Int J Clin Pract 2013;67:606-18.
10. Rees J, Brocksom J, Garner J, Rochester M. Diagnosis, management, and referral of men with lower urinary tract symptoms due to benign prostatic hyperplasia [Internet]. Chesham: Guidelines; c2017 [cited 2019 Dec 28]. Available from: https://www.guidelines.co.uk/mens-health/management-of-luts-with-luts-guideline/453746.article.
11. Schartau P, Kirby M, Horsfall L, Nazareth I, Molokhia M, Sharma M. PS-05-008. Recent trends in incidence of recorded erectile dysfunction, phosphodiesterase type 5 inhibitor prescriptions, hypogonadism and testosterone replacement therapy prescriptions in type 2 diabetic patients in a primary care setting. Paper presented at: 21st Congress of the European Society for Sexual Medicine; 2019 Feb 14-16 Ljubljana, Slovenia. Available from: https://www.essm.org/wp-content/uploads/publications/21st_Congress_of_the_European_Society_for_Sexual_Medicine_Abstract_Supplement_2019.pdf.
12. David J, Edwards D, Wright P. Revitalise audit: erectile dysfunction and testosterone review in primary care. Diabetes Prim Care 2017;19:67-72.
13. Gong B, Ma M, Xie W, Yang X, Huang Y, Sun T, et al. Direct comparison of tadalafl with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol 2017;49:1731-40.
14. Kloner RA, Jackson GA, Emmick JT, Mitchell MI, Bedding A, Warner MR, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafl and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004;172(5 Pt 1):1935-40.
15. Lee JY, Park SY, Jeong TY, Moon HS, Kim YT, Yoo TK, et al. Combined tadalafl and a-blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: a multicenter, prospective study. J Androl 2012;33:397-403.
16. Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et al. Management of non-neurogenic male LUTS [Internet]. Arnhem: European Association of Urology; c2019 [cited 2019 Dec 14]. Available from: https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-the-Management-of-Non-Neurogenic-Male-LUTS-2019.pdf.
17. Hackett G, Kirby M, Wylie K, Heald A, Ossei-Gerning N, Edwards D, et al. British Society for Sexual Medicine guidelines on the management of erectile dysfunction in men-2017. J Sex Med 2018;15:430-57.
18. Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol 2018;200:423-32.
19. American Diabetes Association. Low testosterone [Internet]. Arlington (VA): American Diabetes Association; [cited 2019 Dec 28]. Available from: https://www.diabetes.org/resources/men/low-testosterone.
20. American Association of Clinical Endocrinologists and American College of Endocrinology. Guidelines on the care of patients with obesity [Internet]. Jacksonville (FL): American Association of Clinical Endocrinologists; c2017 [cited 2017 Dec 19]. Available from: https://www.aace.com/publications/guidelines.
21. Hackett G, Kirby M, Edwards D, Jones TH, Wylie K, Ossei-Gerning N, et al. British Society for Sexual Medicine guidelines on adult testosterone deficiency, with statements for UK practice. J Sex Med 2017;14:1504-23.
22. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017;357:j2099.
23. ClinRisk. Welcome to the QRISK®-3-2018 risk calculator https://qrisk.org/three [Internet]. Leeds: ClinRisk; [cited 2019 Dec 28]. Available from: https://qrisk.org/three.
24. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
25. Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005;47:214-20; discussion 220-2.
26. Amano T, Earle C, Imao T, Matsumoto Y, Kishikage T. Administration of daily 5 mg tadalafl improves endothelial function in patients with benign prostatic hyperplasia. Aging Male 2018;21:77-82.
27. Ramirez CE, Nian H, Yu C, Gamboa JL, Luther JM, Brown NJ, et al. Treatment with sildenafil improves insulin sensitivity in prediabetes: a randomized, controlled trial. J Clin Endocrinol Metab 2015;100:4533-40.
28. Santi D, Granata AR, Guidi A, Pignatti E, Trenti T, Roli L, et al. Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial. Eur J Endocrinol 2016;174:513-22.
29. Aversa A, Greco E, Bruzziiches R, Pili M, Rosano G, Spera G.
Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007;19:200-7.

30. Fiore D, Gianfrilli D, Giannetta E, Galea N, Panio G, di Dato C, et al. PDE5 inhibition ameliorates visceral adiposity targeting the miR-22/SIRT1 pathway: evidence from the CECSID trial. J Clin Endocrinol Metab 2016;101:1525-34.

31. Santi D, Giannetta E, Isidori AM, Vitale C, Aversa A, Simon M. Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis. Eur J Endocrinol 2015;172:R103-14.

32. Lee JW, Park HJ, Park NC. Serum high-sensitivity C-reactive protein levels and response to 5 mg tadalafil once daily in patients with erectile dysfunction and diabetes. Korean J Urol 2013;54:858-64.

33. Schwartz BG, Jackson G, Stecher VJ, Campoli-Richards DM, Kloner RA. Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions. Am J Med 2013;126:192-9.

34. Hellstrom WJ, Gittelman M, Jarow J, Steidle C, McMurray J, Talley D, et al. An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study. Eur Urol 2008;53:1058-65.

35. Ozcan L, Polat EC, Kocaaslan R, Onen E, Oztuncemur A, Ozbek E. Effects of taking tadalafil 5 mg once daily on erectile function and total testosterone levels in patients with metabolic syndrome. Andrologia 2017;49. doi: 10.1111/and.12751.

36. Spitzer M, Basaria S, Travison TG, Davda MN, Paley A, Cohen B, et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med 2012;157:681-91.

37. Park HJ, Hyun JS, Park NC. A comparison of baseline erectile function after on-demand 20 mg tadalafil vs daily 5 mg tadalafil in men with erectile dysfunction and diabetes: a prospective, observational 2-year study. Eur Urol Supp 2014;13:e602.

38. Buvat J, Hatzichristou D, Boess FG, Büttner H, Gehchan N, Henneges C, et al. Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDATE study. Int J Clin Pract 2014;68:1087-99.

39. Brock G, Ni X, Oelke M, Mulhall J, Rosenberg M, Seftel A, et al. Efficacy of continuous dosing of tadalafil once daily vs tadalafil on demand in clinical subgroups of men with erectile dysfunction: a descriptive comparison using the integrated tadalafil databases. J Sex Med 2016;13:860-75.

40. Bansal UK, Jones C, Fuller TW, Wessel C, Jackman SV. The efficacy of tadalafil daily vs on demand in the treatment of erectile dysfunction: a systematic review and meta-analysis. Urology 2018;112:6-11.

41. Peng Z, Yang L, Dong Q, Wei Q, Liu L, Yang B. Efficacy and safety of tadalafil once-a-day versus tadalafil on-demand in patients with erectile dysfunction: a systematic review and meta-analyses. Urol Int 2017;99:343-52.

42. Prasetyo DT, Raharja PÄ, Mantiri BJ, Ringoringo DRL, Rahman IA, Felizio J, et al. Tadalafil once a day for men with erectile dysfunction: Is it superior than on-demand administration? Acta Med Indones 2019;51:275-81.

43. Zhou Z, Chen H, Wu J, Wang J, Zhang X, Ma J, et al. Meta-analysis of the long-term efficacy and tolerance of tadalafil daily compared with tadalafil on-demand in treating men with erectile dysfunction. Sex Med 2019;7:282-91.

44. Shahfik A, Shahfik I, El Sibai O, Shahfik AA. On the pathogenesis of penile venous leakage: role of the tunica albuginea. BMC Urol 2007;7:14.

45. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005;2:415-25; discussion 425-7.

46. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med 2009;6:1232-47.

47. Ma RC, So WY, Yang X, Yu LW, Kong AP, Ko GT, et al. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol 2008;51:2045-50.

48. Koskimäki J, Shiri R, Tammela T, Hääkkinen J, Hakama M, Auvinen A. Regular intercourse protects against erectile dysfunction: Tampere aging male urologic study. Am J Med 2008;121:592-6.

49. Regional Drug and Therapeutics Centre. Cost comparison charts [Internet]. Newcastle upon Tyne: Regional Drug and Therapeutics Centre; c2019 [cited 2019 Dec 23]. Available from: http://gmmmg.nhs.uk/docs/cost_comparison_charts.pdf.

50. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-49.

51. Andersson KE. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery. Br J Pharmacol 2018;175:2554-65.

52. Oelke M, Giuliano F, Mironir V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, place-
bo-controlled clinical trial. Eur Urol 2012;61:917-25.
53. Oelke M, Giuliano F, Baygani SK, Melby T, Sontag A. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study. BJU Int 2014;114:568-75.
54. Roehrborn CG, Chapple C, Oelke M, Cox D, Esler A, Viktrup L. Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. J Urol 2014;191:1045-50.
55. Pogula VR, Kadiyala LS, Gourru VR, Challia SR, Byram R, Boduluri S. Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized study. Cent European J Urol 2019;72:44-50.
56. Hatzimouratidis K. A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction. Ther Adv Urol 2014;6:135-47.
57. Donatucci CF, Wong DG, Giuliano F, Gлина S, Dowsett SA, Watts S, et al. Efficacy and safety of tadalafil once daily: considerations for the practical application of a daily dosing option. Curr Med Res Opin 2008;24:3383-92.
58. Yang DY, Jeong HC, Ko K, Lee SH, Lee SK, Shin TY, et al. Effect of tadalafil 5 mg on post-micturition dribble in men with lower urinary tract symptoms: a multicentre, double-blind, randomized, placebo-controlled trial. BJU Int 2019;124:862-9.
59. Wei L, Lai EC, Kao-Yang YH, Walker BR, MacDonald TM, Andrew R. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study. BMJ 2019;365:l1204.
60. Olesovsny C, Kapoor A. Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia. Ther Adv Urol 2016;8:257-71.
61. Schimke L, Schinike J. Urological implications of falls in the elderly: lower urinary tract symptoms and alpha-blocker medications. Urol Nurs 2014;34:223-9.
62. Marberger M. The MTOPS Study: new findings, new insights, and clinical implications for the management of BPH. Eur Urol Supp 2006;5:628-33.
63. Gacci M, Andersson KE, Chapple C, Maggi M, Mironov V, Oelke M, et al. Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2016;70:124-33.
64. Seftel AD, de la Rosette J, Birt J, Porter V, Zarotsky V, Viktrup L. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int J Clin Pract 2013;67:32-45.
65. Pofi R, Gianfrilli D, Badagliacca R, Di Dato C, Venneri MA, Giannetta E. Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): how do they work? J Endocrinol Invest 2016;39:131-42.
66. Cai Z, Zhang J, Li H. Two birds with one stone: regular use of PDE5 inhibitors for treating male patients with erectile dysfunction and cardiovascular diseases. Cardiovasc Drugs Ther 2019;33:119-28.
67. Hutchings DC, Anderson SG, Caldwell JL, Trafford AW. Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? Heart 2018;104:1244-50.
68. Anderson SG, Hutchings DC, Woodward M, Rahimi K, Rutten MK, Kirby M, et al. Phosphodiesterase-type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart 2016;102:1750-6.
69. Hackett G, Heald AH, Sinclair A, Jones PW, Strange RC, Ramachandran S. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins. Int J Clin Pract 2016;70:244-53.
70. Andersson DP, Trolle Lagerros Y, Grotta A, Bellocco R, Lehtihet M, Holzmann MJ. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart 2017;103:1264-70.
71. Scraton RE, Goldstein I, Stecher VJ. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management. J Sex Med 2013;10:551-61.
72. Hackett G. PDE5 inhibitors in diabetic peripheral neuropathy. Int J Clin Pract 2006;60:1123-6.
73. Sairam K, McNicholas TA. Sildenafil in diabetic peripheral neuropathy. Br J Diabetes Vasc Dis 2002;2:304.
74. Afzar B, Ortiz A, Covic A, Gairow A, Eshen T, Goldsmith D, et al. Phosphodiesterase type 5 inhibitors and kidney disease. Int Urol Nephrol 2015;47:1521-8.
75. Barone I, Giordano C, Bonofiglio D, Catalano S, Ando S. Phosphodiesterase type 5 as a candidate therapeutic target in cancers. Curr Pathobiol Rep 2015;3:193-201.
76. Huang W, Sundquist J, Sundquist K, Ji J. Use of phosphodiesterase 5 inhibitors is associated with lower risk of colorectal cancer in men with benign colorectal neoplasms. Gastroenterology 2019;157:672-81.e4.
77. Choi JB, Cho KJ, Kim JC, Kim CH, Chung YA, Jeong HS, et al. The effect of daily low dose tadalafil on cerebral perfusion and cognition in patients with erectile dysfunction and
mild cognitive impairment. Clin Psychopharmacol Neurosci 2019;17:432-7.

78. Urios A, Ordoño F, García-García R, Mangas-Losada A, Leone P, José Gallego J, et al. Tadalafil treatment improves inflammation, cognitive function, and mismatch negativity of patients with low urinary tract symptoms and erectile dysfunction. Sci Rep 2019;9:17119.

79. Corona G, Giorda CB, Cucinotta D, Guida P, Nada E; Gruppo di studio SUBITO-DE. Sexual dysfunction at the onset of type 2 diabetes: the interplay of depression, hormonal and cardiovascular factors. J Sex Med 2014;11:2065-73.

80. de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001;63:619-30.

81. Nurnberg HG, Seidman SN, Gelenberg AJ, Fava M, Rosen R, Shabsigh R. Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. Urology 2002;60(2 Suppl 2):58-66.

82. Shim YS, Pae CU, Kim SW, Kim HW, Kim JC, Koh JS. Effects of repeated dosing with Udenafil (Zydena) on cognition, somatization and erection in patients with erectile dysfunction: a pilot study. Int J Impot Res 2011;23:109-14.